Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Breast Neoplasms 1277Carcinoma, Non-Small-Cell Lung 926Prostatic Neoplasms 729Neoplasms 632Multiple Myeloma 553Lymphoma 539Colorectal Neoplasms 529Lung Neoplasms 515Leukemia 497Leukemia, Myeloid, Acute 472Neoplasm Metastasis 470Melanoma 425Lymphoma, Non-Hodgkin 417Ovarian Neoplasms 416Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 335Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Head and Neck Neoplasms 306Lymphoma, Large B-Cell, Diffuse 294Glioblastoma 294Myelodysplastic Syndromes 287Brain Neoplasms 287Lymphoma, Follicular 286Stomach Neoplasms 280Carcinoma, Renal Cell 268Hodgkin Disease 261Carcinoma, Hepatocellular 261Rectal Neoplasms 256Sarcoma 250

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Completed × Osteolysis × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡